A practical guide to biologic treatments for psoriasis in resource-limited areas
Issued Date
2025-09-01
Resource Type
ISSN
0125877X
Scopus ID
2-s2.0-105020775879
Pubmed ID
41182245
Journal Title
Asian Pacific Journal of Allergy and Immunology
Volume
43
Issue
3
Start Page
410
End Page
421
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology Vol.43 No.3 (2025) , 410-421
Suggested Citation
Chularojanamontri L., Pongcharoen P., Rattanakaemakorn P., Asawanonda P. A practical guide to biologic treatments for psoriasis in resource-limited areas. Asian Pacific Journal of Allergy and Immunology Vol.43 No.3 (2025) , 410-421. 421. doi:10.12932/AP-240425-2072 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113044
Title
A practical guide to biologic treatments for psoriasis in resource-limited areas
Corresponding Author(s)
Other Contributor(s)
Abstract
Biologic therapies have transformed the management of moderate to severe psoriasis, providing targeted and effective interventions against key inflammatory pathways. Due to their action specifications compared to conventional therapies, they generally provide better efficacy-safety profiles, especially the second-generation of biologics for psoriasis. Furthermore, the broader aspects of patients' quality of life can improve dramatically. This review overviews the efficacy, safety, and real-world application of biologic agents, including tumor necrosis factor-alpha inhibitors, interleukin (IL)-12/23 inhibitors, IL-17 inhibitors and IL-23 inhibitors. Their effectiveness in difficult-to-treat areas such as the scalp, nails, palmoplantar region, and genital area, where conventional treatments often fail is also highlighted. Immunogenicity differences between biologics, along with variations in binding affinity and half-life, may influence treatment response and drug persistence. Intra-class and inter-class biologic switching have been utilized to optimize treatment outcomes in patients experiencing inadequate response or adverse effects. Long-term data suggest that biologics are well-tolerated, with a favorable safety profile. As biologic options continue to expand, individualized treatment selection such as patients' comorbidities, prior treatment history, and real-world drug survival are essential for optimizing patient outcomes in psoriasis management.